BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 16166655)

  • 21. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max.
    Amati B; Dalton S; Brooks MW; Littlewood TD; Evan GI; Land H
    Nature; 1992 Oct; 359(6394):423-6. PubMed ID: 1406955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The mechanism of discrimination between cognate and non-specific DNA by dimeric b/HLH/LZ transcription factors.
    Sauvé S; Naud JF; Lavigne P
    J Mol Biol; 2007 Jan; 365(4):1163-75. PubMed ID: 17109882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Max homodimeric b-HLH-LZ significantly interferes with the specific heterodimerization between the c-Myc and Max b-HLH-LZ in absence of DNA: a quantitative analysis.
    McDuff FO; Naud JF; Montagne M; Sauvé S; Lavigne P
    J Mol Recognit; 2009; 22(4):261-9. PubMed ID: 19189276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain.
    Ferré-D'Amaré AR; Prendergast GC; Ziff EB; Burley SK
    Nature; 1993 May; 363(6424):38-45. PubMed ID: 8479534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1.
    Rao G; Alland L; Guida P; Schreiber-Agus N; Chen K; Chin L; Rochelle JM; Seldin MF; Skoultchi AI; DePinho RA
    Oncogene; 1996 Mar; 12(5):1165-72. PubMed ID: 8649810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thermodynamics of b-HLH-LZ protein binding to DNA: the energetic importance of protein-DNA contacts in site-specific E-box recognition by the complete gene product of the Max p21 transcription factor.
    Meier-Andrejszki L; Bjelić S; Naud JF; Lavigne P; Jelesarov I
    Biochemistry; 2007 Oct; 46(43):12427-40. PubMed ID: 17915948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The N-myc oncoprotein is a transcriptional activator and associates with max and RB1 proteins.
    Wenzel A; Cziepluch C; Schürmann J; Schwab M
    Prog Clin Biol Res; 1994; 385():59-66. PubMed ID: 7972238
    [No Abstract]   [Full Text] [Related]  

  • 28. Elucidation of the structural determinants responsible for the specific formation of heterodimeric Mxd1/Max b-HLH-LZ and its binding to E-box sequences.
    Montagne M; Naud JF; Lavigne P
    J Mol Biol; 2008 Feb; 376(1):141-52. PubMed ID: 18155722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of casein kinase II phosphorylation sites in Max: effects on DNA-binding kinetics of Max homo- and Myc/Max heterodimers.
    Bousset K; Henriksson M; Lüscher-Firzlaff JM; Litchfield DW; Lüscher B
    Oncogene; 1993 Dec; 8(12):3211-20. PubMed ID: 8247525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural and thermodynamical characterization of the complete p21 gene product of Max.
    Naud JF; McDuff FO; Sauvé S; Montagne M; Webb BA; Smith SP; Chabot B; Lavigne P
    Biochemistry; 2005 Sep; 44(38):12746-58. PubMed ID: 16171389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif.
    Hurlin PJ; Steingrìmsson E; Copeland NG; Jenkins NA; Eisenman RN
    EMBO J; 1999 Dec; 18(24):7019-28. PubMed ID: 10601024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of apoptosis by the c-Myc helix-loop-helix/leucine zipper domain in mouse 3T3-L1 fibroblasts.
    Kohlhuber F; Hermeking H; Graessmann A; Eick D
    J Biol Chem; 1995 Dec; 270(48):28797-805. PubMed ID: 7499403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis.
    Soucek L; Jucker R; Panacchia L; Ricordy R; Tatò F; Nasi S
    Cancer Res; 2002 Jun; 62(12):3507-10. PubMed ID: 12067996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of a variant Max sequence expressed in Xenopus laevis.
    Tonissen KF; Krieg PA
    Oncogene; 1994 Jan; 9(1):33-8. PubMed ID: 8302600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myc protein structure: localization of DNA-binding and protein dimerization domains.
    Kerkhoff E; Bister K
    Oncogene; 1991 Jan; 6(1):93-102. PubMed ID: 1992448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. v-Myc, but not Max, possesses domains that function in both transcription activation and cellular transformation.
    Min S; Taparowsky EJ
    Oncogene; 1992 Aug; 7(8):1531-40. PubMed ID: 1630816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc.
    Austen M; Cerni C; Lüscher-Firzlaff JM; Lüscher B
    Oncogene; 1998 Jul; 17(4):511-20. PubMed ID: 9696045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The leucine zippers of the HLH-LZ proteins Max and c-Myc preferentially form heterodimers.
    Muhle-Goll C; Nilges M; Pastore A
    Biochemistry; 1995 Oct; 34(41):13554-64. PubMed ID: 7577944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence.
    Giorello L; Clerico L; Pescarolo MP; Vikhanskaya F; Salmona M; Colella G; Bruno S; Mancuso T; Bagnasco L; Russo P; Parodi S
    Cancer Res; 1998 Aug; 58(16):3654-9. PubMed ID: 9721875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of transcriptional repression by max homodimers.
    Yin X; Grove L; Prochownik EV
    Oncogene; 1998 May; 16(20):2629-37. PubMed ID: 9632139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.